Solvias, an independent pharmaceutical testing and manufacturing companies, acquired Utrecht, Netherlands-based Cergentis. The acquisition was made to bolster Solvias’ platform of biologics and cell and gene therapy (CGT) testing solutions.

According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more researchers leverage emerging genetic engineering techniques to develop complex, novel medicines, they require sophisticated solutions to analyze their safety and effectiveness.

With the addition of Cergentis, Solvias’ CEO Archie Cullen says the company will continue to support the increasing number of global pharmaceutical, biotech, and CDMOs developing genetically engineered therapies with an expanded platform of testing services. Cullen specifically cited Solvias’ expertise in emerging genome techniques and evolving regulatory requirements, proprietary genomic analysis, a global network serving customers across three continents, customized support for distinct genetic engineering applications, including cell and gene therapy, cell line development & genetically engineered models, and specialized knowledge in genomic sequencing of early-stage cell lines.

“We are relentlessly focused on ensuring the safety of new therapies in development,” continues Cullen. “Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies. We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry.”

“We are excited to become part of a global leader that complements our scientific expertise, innovation and customer service,” adds Joris Schuurmans, CEO, Cergentis, who is joining Solvias’ leadership team and will continue to lead operations for Cergentis.